Answers are grounded in this paper and cite their sources.
// Euan A. Stronach 1 , Paula Cunnea 1 , Christina Turner 2 , Tankut Guney 2 , Radhika Aiyappa 3 , Senthuran Jeyapalan 2 , Camila H. de Sousa 1 , Alacoque Browne 2 , Nesreen Magdy 2, 4 , James B. Studd 1 , Ruethairat Sriraksa 5 , Hani Gabra 1 , Mona El-Bahrawy 2, 6 1 Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK 2 Department of Histopathology, Imperial College London, Hammersmith Hospital, London, UK 3 Division of Molecular Medicine, St. John's Research Institute, Bangalore, India 4 Department of Pathology, National Cancer Institute, Cairo University, Egypt 5 Epigenetics Group, International Agency for Research on Cancer, Lyon, France 6 Department of Pathology, Faculty of Medicine, University of Alexandria, Egypt Correspondence to: Mona El-Bahrawy, e-mail: m.elbahrawy@imperial.ac.uk Keywords: ovary, carcinoma, cytokine, interleukin-8, chemoresistance Received: November 30, 2014 Accepted: February 19, 2015 Published: March 23, 2015 ABSTRACT Platinum based drugs are the cornerstone of chemotherapy for ovarian cancer, however the development of chemoresistance hinders its success. IL-8 is involved in regulating several pro-survival pathways in cancer. We studied the expression of IL-8 and IL-8 receptors in platinum sensitive and resistant cell lines. Using qRT-PCR and immunohistochemistry, both platinum sensitive (PEA1, PEO14) and resistant (PEA2, PEO23) show increased expression of IL-8 and IL-8 receptors. IL-8RA shows nuclear and cytoplasmic expression, whilst IL-8RB is present solely in the cytoplasm. Knockdown of IL-8 increased sensitivity to cisplatin in platinum sensitive and reversed platinum resistance in resistant cell lines, decreased the expression of anti-apoptotic Bcl-2 and decreased inhibitory phosphorylation of pro-apoptotic Bad. IL-8 receptor antagonist treatment also enhanced platinum sensitivity. Nuclear localisation of IL-8RA was only detected in platinum resistant tumours. Inhibition of IL-8 signalling can enhance response in platinum sensitive and resistant disease. Nuclear IL-8RA may have potential as a biomarker of resistant disease.
No takes yet. Share an insight, caveat, or question.
Stronach et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: